• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Excellent Anti-Tumour Strategy (CTGVT, OV-gene) and the Excellent Anti-Tumor Gene (IL-24).

作者信息

Liu Xin-Yuan

机构信息

State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, China; ; Xin Yuan Institute of Medicine and Biotechnology, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China.

出版信息

Int J Biomed Sci. 2012 Jun;8(2):87-93.

PMID:23675261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3614863/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/33ba96cc6b87/IJBS-8-87_F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/097326ffea18/IJBS-8-87_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/cb4d25091ecd/IJBS-8-87_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/135141170300/IJBS-8-87_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/2b973c99c64a/IJBS-8-87_F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/33ba96cc6b87/IJBS-8-87_F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/097326ffea18/IJBS-8-87_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/cb4d25091ecd/IJBS-8-87_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/135141170300/IJBS-8-87_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/2b973c99c64a/IJBS-8-87_F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/816f/3614863/33ba96cc6b87/IJBS-8-87_F5.jpg

相似文献

1
The Excellent Anti-Tumour Strategy (CTGVT, OV-gene) and the Excellent Anti-Tumor Gene (IL-24).卓越抗肿瘤策略（CTGVT，OV-基因）和卓越抗肿瘤基因（IL-24）。
Int J Biomed Sci. 2012 Jun;8(2):87-93.
2
A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect.携带双重肿瘤抑制基因的新型溶瘤腺病毒载体显示出强大的抗肿瘤作用。
J Cell Mol Med. 2012 Jun;16(6):1298-309. doi: 10.1111/j.1582-4934.2011.01396.x.
3
Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy.癌症靶向基因-病毒治疗策略（CTGVT）是癌症基因治疗和癌症病毒治疗的一个趋势。
Curr Pharm Biotechnol. 2012 Jul;13(9):1761-7. doi: 10.2174/138920112800958869.
4
Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.干扰素-γ在白细胞介素12诱导的肿瘤消退介导中的多种作用。
Cancer Res. 1998 Jun 1;58(11):2426-32.
5
Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice.使用溶瘤腺病毒 ZD55-IL-24 对免疫功能正常的小鼠进行癌症靶向基因-病毒-治疗胰腺癌。
Mol Biol Rep. 2013 Sep;40(9):5397-405. doi: 10.1007/s11033-013-2638-8. Epub 2013 May 11.
6
A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy.理性的关联：溶瘤病毒疫苗作为过继性 T 细胞疗法的功能伙伴。
Cytokine Growth Factor Rev. 2020 Dec;56:149-159. doi: 10.1016/j.cytogfr.2020.07.003. Epub 2020 Jul 3.
7
Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy.CTGVT-DG 策略中 TRAIL 和 IL-24 的协同抗肿瘤作用可完全根除肝癌。
Acta Biochim Biophys Sin (Shanghai). 2012 Jun;44(6):535-43. doi: 10.1093/abbs/gms031.
8
Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12.白细胞介素12给药后，极晚期抗原4/淋巴细胞功能相关抗原1依赖性T细胞向肿瘤部位迁移的诱导增强。
Cancer Res. 1997 Jun 1;57(11):2216-22.
9
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.使用组蛋白去乙酰化酶抑制剂和免疫检查点阻断克服溶瘤病毒疗法中的障碍。
Viruses. 2016 Jan 6;8(1):9. doi: 10.3390/v8010009.
10
Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.溶瘤病毒编码主炎症细胞因子白细胞介素 12 在癌症免疫治疗中的应用。
Cells. 2020 Feb 10;9(2):400. doi: 10.3390/cells9020400.

引用本文的文献

1
In Vivo Oncolytic Virotherapy in Murine Models of Hepatocellular Carcinoma: A Systematic Review.小鼠肝细胞癌模型中的体内溶瘤病毒疗法：一项系统综述。
Vaccines (Basel). 2022 Sep 16;10(9):1541. doi: 10.3390/vaccines10091541.
2
Combination Therapy of Prostate Cancer by Oncolytic Adenovirus Harboring Interleukin 24 and Ionizing Radiation.携带白细胞介素24的溶瘤腺病毒与电离辐射联合治疗前列腺癌
Front Oncol. 2020 Apr 3;10:421. doi: 10.3389/fonc.2020.00421. eCollection 2020.
3
Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer.

本文引用的文献

1
Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy.CTGVT-DG 策略中 TRAIL 和 IL-24 的协同抗肿瘤作用可完全根除肝癌。
Acta Biochim Biophys Sin (Shanghai). 2012 Jun;44(6):535-43. doi: 10.1093/abbs/gms031.
2
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.静脉注射多机制癌症靶向溶瘤痘病毒在人体中的应用。
Nature. 2011 Aug 31;477(7362):99-102. doi: 10.1038/nature10358.
3
Cancer targeting gene-viro-therapy specific for liver cancer by α-fetoprotein-controlled oncolytic adenovirus expression of SOCS3 and IL-24.
携带白细胞介素-24的溶瘤腺病毒改善晚期前列腺癌化疗效果。
J Cancer. 2018 Oct 22;9(23):4391-4397. doi: 10.7150/jca.26437. eCollection 2018.
4
GOLPH2-regulated oncolytic adenovirus, GD55, exerts strong killing effect on human prostate cancer stem-like cells in vitro and in vivo.GOLPH2 调控的溶瘤腺病毒 GD55 在体外和体内对人前列腺癌干细胞样细胞具有强大的杀伤作用。
Acta Pharmacol Sin. 2018 Mar;39(3):405-414. doi: 10.1038/aps.2017.91. Epub 2017 Sep 7.
5
GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells.GP73调控的溶瘤腺病毒对人肝癌干细胞样细胞具有强大的杀伤作用。
Oncotarget. 2016 May 17;7(20):29346-58. doi: 10.18632/oncotarget.8830.
6
Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.载瘤胃抑素的溶瘤腺病毒联合 TRAIL 和 MnSOD 对肺癌的增效作用。
Cancer Gene Ther. 2016 Jun;23(6):168-77. doi: 10.1038/cgt.2016.11. Epub 2016 Apr 15.
甲胎蛋白调控的溶瘤腺病毒表达 SOCS3 和 IL-24 对肝癌的靶向基因-病毒治疗。
Acta Biochim Biophys Sin (Shanghai). 2011 Oct;43(10):813-21. doi: 10.1093/abbs/gmr071. Epub 2011 Aug 11.
4
Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy.癌症靶向基因-病毒治疗策略（CTGVT）是癌症基因治疗和癌症病毒治疗的一个趋势。
Curr Pharm Biotechnol. 2012 Jul;13(9):1761-7. doi: 10.2174/138920112800958869.
5
Recent deal highlights hopes for cancer-killing viruses.近期交易凸显了对抗癌病毒的期望。
Nat Med. 2011 Mar;17(3):268-9. doi: 10.1038/nm0311-268b.
6
Targeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene.靶向 DD3 驱动的溶瘤病毒携带白细胞介素 24 基因的前列腺癌基因-病毒治疗。
Int J Cancer. 2010 Aug 1;127(3):707-17. doi: 10.1002/ijc.25069.
7
VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis.VEGI 武装的溶瘤腺病毒抑制肿瘤新生血管形成，并直接诱导线粒体介导的癌细胞凋亡。
Cell Res. 2010 Mar;20(3):367-78. doi: 10.1038/cr.2009.126. Epub 2009 Nov 17.
8
Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.溶瘤腺病毒介导的人生长抑素受体基因2基因的重新表达增强了肿瘤坏死因子相关凋亡诱导配体对胰腺癌的抗肿瘤活性。
Clin Cancer Res. 2009 Aug 15;15(16):5154-60. doi: 10.1158/1078-0432.CCR-09-0025. Epub 2009 Aug 11.
9
Targeting gene-virotherapy of cancer and its prosperity.癌症的靶向基因病毒疗法及其前景。
Cell Res. 2006 Nov;16(11):879-86. doi: 10.1038/sj.cr.7310108.
10
The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.TRAIL与IL-24联合复制型溶瘤腺病毒在结直肠癌中的抗肿瘤活性。
Cancer Gene Ther. 2006 Nov;13(11):1011-22. doi: 10.1038/sj.cgt.7700969. Epub 2006 Jun 23.